Sensei Biotherapeutics, Inc. SNSE
13.85 USD 0.00 (+0.00%)
At closeJun 15, 2026, 4:00 PM EDT
14.01 +0.16 +1.16%
After hours · Jun 15, 4:00 PM ET
13.76 Day range 16.52
52-week range unavailable
- YTD
- +29.80%
- 1 year
- +85.16%
Analyst view
Price target (mean) 4.13 -70.2% downside
Now 13.85
- Target (low)
- 3.50
- Target (mean)
- 4.13
- Target (high)
- 5.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 4
- 2 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.29984 | -0.30 – -0.29968 | -0.30 | +0.1% | 0 | 0.0% | 2 |
| Current year | -1.16 | -1.19 – -1.14 | -1.21 | +3.7% | 0 | 0.0% | 2 |
| Next year | -1.30 | -1.42 – -1.17 | -1.16 | -11.4% | 0 | 0.0% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 24, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 24, 2024 | Stephens & Co. | Reiterated | Overweight | Overweight |
| May 14, 2024 | Stephens & Co. | Initiated | — | Overweight |
| Dec 4, 2023 | HC Wainwright & Co. | Initiated | — | Buy |
| Dec 13, 2022 | Citigroup | Initiated | — | Buy |
| Oct 3, 2022 | Oppenheimer | Upgrade | Perform | Outperform |
| Mar 10, 2022 | Piper Sandler | Maintained | — | Overweight |
| Jul 1, 2021 | Berenberg | Downgrade | Buy | Hold |
| Jun 29, 2021 | Oppenheimer | Downgrade | Outperform | Perform |
| Mar 1, 2021 | Oppenheimer | Initiated | — | Outperform |
| Mar 1, 2021 | Piper Sandler | Initiated | — | Overweight |